CLEVELAND, April 22 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported a multi-year agreement with the Portuguese CRO Keypoint - Consultoria cientifica, Lda. As the newest member of DATATRAK's CRO Connect Program(TM), Keypoint is able to expand its electronic data capture (EDC) capabilities and empower its staff to more efficiently manage both its paper and EDC studies.
"DATATRAK's eClinical(TM) is the platform that will give our customers a valuable solution on CDMS/EDC for clinical trials," said Keypoint CFO, Hugo Pedrosa. "We look at DATATRAK not only as a solution provider but as a partner who will bring added value to our services."
"We welcome Keypoint as the newest member of the CRO Connect Program(TM)," said DATATRAK CEO, Larry Birch. "Keypoint joins a growing list of CROs who are benefiting from our DATATRAK eClinical(TM) platform, specialized pricing and joint marketing of the CRO Connect Program. We look forward to supporting Keypoint as they broaden their service offering and develop new revenue streams utilizing our platform."
DATATRAK's CRO Connect Program is a collaborative initiative with CROs that offers the benefits of our comprehensive DATATRAK eClinical(TM) solution through an innovative Enterprise Transfer program. This program allows CROs to package their services around our eClinical(TM) platform in order to gain efficiencies and increased market share. The CRO Connect Program's flexible pricing and specialized consulting and professional services provides participants with the tools necessary to realize new growth opportunities.
Keypoint is a Portuguese CRO who specializes in observational studies. To date, Keypoint has collaborated in more than 150 observational studies, in Portugal, in all major therapeutic areas, including Oncology, Cardiology, Internal Medicine, CNS and Infectious Diseases. Keypoint's Mission is to provide methodological support to the scientific investigation in health domain, scientific advisory, information management, methodological advisory, statistical analysis, development of epidemiologic studies and clinical trials, and training actions, bearing in mind our clients' demands and their specific needs. Visit the Keypoint web site at www.keypoint.pt.
About DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. The DATATRAK eClinical(TM) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Its common stock is listed on the NASDAQ Stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; delisting of the Company's common shares from the Nasdaq Capital Market; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
|SOURCE DATATRAK International, Inc.|
Copyright©2009 PR Newswire.
All rights reserved